You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

TECHNELITE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TECHNELITE?
  • What are the global sales for TECHNELITE?
  • What is Average Wholesale Price for TECHNELITE?
Summary for TECHNELITE
US Patents:0
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 6
What excipients (inactive ingredients) are in TECHNELITE?TECHNELITE excipients list
DailyMed Link:TECHNELITE at DailyMed
Drug patent expirations by year for TECHNELITE

US Patents and Regulatory Information for TECHNELITE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl TECHNELITE technetium tc-99m sodium pertechnetate generator SOLUTION;INTRAVENOUS 017771-002 Feb 12, 2014 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Lantheus Medcl TECHNELITE technetium tc-99m sodium pertechnetate generator SOLUTION;INTRAVENOUS 017771-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

TECHNELITE Market Analysis and Financial Projection Experimental

Technetium-99m and TechneLite: Market Dynamics and Financial Trajectory

Introduction

Technetium-99m (Tc-99m) is a crucial radiopharmaceutical widely used in medical diagnostics, particularly in imaging procedures. One of the key products in this market is TechneLite, a Tc-99m generator produced by Lantheus Holdings, Inc. This article delves into the market dynamics and financial trajectory of TechneLite, highlighting its significance, market growth, and financial performance.

Market Overview of Technetium-99m

The Technetium-99m market was valued at US$ 6.0 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 3.3% from 2024 to 2034, reaching US$ 8.6 billion by the end of the forecast period[1][4].

Drivers of Market Growth

Several factors are driving the growth of the Tc-99m market, including:

  • Expansion of Health Infrastructure: Increasing investment in healthcare infrastructure globally is a significant driver.
  • Rise in Healthcare Expenditure: Higher healthcare spending and initiatives emphasizing advanced medical technologies are boosting demand.
  • COVID-19 Pandemic Impact: The pandemic highlighted the need for enhanced investment in global Human Resources for Health (HRH), which indirectly supports the growth of the Tc-99m market[1][4].

Role of TechneLite

TechneLite is a Tc-99m generator that plays a critical role in providing the radiopharmaceutical for various diagnostic imaging procedures. As of December 31, 2020, TechneLite held approximately one-third of the U.S. generator market, competing primarily with other Tc-99m-based generators[3].

Market Segmentation and Regional Outlook

The Tc-99m market, including TechneLite, is segmented across various regions:

  • North America: This region is the largest market due to advanced healthcare infrastructure and high levels of healthcare investment.
  • Europe: Strong healthcare systems and ongoing research into new uses for radiopharmaceuticals drive the market here.
  • Asia-Pacific: Countries like Japan, China, and India are experiencing rapid growth due to investments in healthcare infrastructure and a growing focus on advanced diagnostics[4].

Financial Performance of Lantheus Holdings, Inc.

Lantheus Holdings, Inc., the company behind TechneLite, has shown significant financial growth:

  • Revenue Growth: In the third quarter of 2024, Lantheus reported worldwide revenue of $378.7 million, an increase of 18.4% from the third quarter of 2023[2][5].
  • Product Sales: Sales of TechneLite, although slightly declining in the third quarter of 2024 with a 12% decrease, still contribute significantly to the company's overall revenue. Other products like PYLARIFY and DEFINITY saw substantial growth, with PYLARIFY increasing by 20.6% and DEFINITY by 14.3%[2][5].
  • Operating Income: Operating income increased by 19.0% to $133.7 million, and adjusted operating income (non-GAAP) increased by 18.3% to $165.1 million[2][5].
  • Cash and Cash Equivalents: The company's cash and cash equivalents grew to $866.4 million as of September 30, 2024, indicating strong financial health[2][5].

Strategic Partnerships and Investments

Lantheus has been active in securing strategic partnerships and making investments to enhance its product portfolio and supply chain:

  • Acquisitions and Investments: The company has made significant investments, including the acquisition of RM2 from Life Molecular and an equity investment in Radiopharm Theranostics. These moves are aimed at expanding its radiopharmaceutical pipeline and improving supply chain efficiency[2][5].

Technological Advancements

Technological improvements in radiopharmaceutical production are crucial for the Tc-99m market:

  • Efficient Production Methods: The development of more efficient cyclotron-based production methods is addressing supply challenges and ensuring a steady supply of high-quality Tc-99m[4].

Competitive Landscape

The Tc-99m market is competitive, with several key players driving innovation and market growth:

  • Collaborations and Mergers: The market is characterized by an increasing focus on collaborations and mergers to enhance product portfolios, improve supply chains, and invest in next-generation radiopharmaceuticals[4].

Future Outlook

The future outlook for TechneLite and the broader Tc-99m market is promising:

  • Growing Demand: The increasing demand for high-quality diagnostic imaging, particularly in non-invasive procedures like SPECT and Gamma Cameras, will continue to drive the market.
  • New Medical Centers and Diagnostic Facilities: The rise of new medical centers and diagnostic facilities, especially in the Asia-Pacific region, will further support market growth[4].

Key Takeaways

  • The Technetium-99m market, including TechneLite, is projected to grow significantly due to its essential role in medical diagnostics.
  • Lantheus Holdings, Inc. has shown strong financial performance, driven by revenue growth and strategic partnerships.
  • Technological advancements and investments in radiopharmaceutical production are addressing supply challenges and enhancing market growth.
  • The market is expected to expand across various regions, with North America, Europe, and Asia-Pacific leading the way.

FAQs

What is the projected growth rate of the Technetium-99m market?

The Technetium-99m market is projected to grow at a CAGR of 3.3% from 2024 to 2034[1][4].

Which regions are leading the growth in the Technetium-99m market?

North America, Europe, and Asia-Pacific are the leading regions in the Technetium-99m market[4].

What is the significance of TechneLite in the Tc-99m market?

TechneLite is a Tc-99m generator that holds approximately one-third of the U.S. generator market and plays a critical role in providing the radiopharmaceutical for diagnostic imaging procedures[3].

How has Lantheus Holdings, Inc. performed financially in recent quarters?

Lantheus Holdings, Inc. reported an 18.4% increase in worldwide revenue in the third quarter of 2024 compared to the same period in 2023, with operating income increasing by 19.0%[2][5].

What are the key drivers of the Technetium-99m market growth?

Key drivers include the expansion of health infrastructure, rise in healthcare expenditure, and technological advancements in radiopharmaceutical production[1][4].

Sources

  1. Transparency Market Research - Technetium-99m Market Size, Share, Growth & Overview, 2034
  2. Lantheus Holdings, Inc. - Lantheus Reports Third Quarter 2024 Financial Results
  3. Lantheus Holdings, Inc. - Investor Relations
  4. GlobeNewswire - Technetium-99m Market Poised for Growth, Projected to Reach Over US$ 8.6 Billion by 2034
  5. GlobeNewswire - Lantheus Reports Third Quarter 2024 Financial Results

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.